RxDoctor Payments Data

Amar Patel, MD

Retina Specialist · Tyler, TXNPI 1871882449

Payments from drug & device makers

$1,767in general payments, 2019–2025

Across 45 payments — averaging $39.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alimera Sciences, Inc.$460
  • Apellis Pharmaceuticals, Inc.$248
  • Regeneron Healthcare Solutions, Inc.$236
  • AbbVie$146
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$93
  • Genentech USA, Inc.$92
  • plus $492 from 10 others

What the payments were for

  • Food & beverage$1,74699%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,767 in reported general payments places this provider in the 35th percentile of 108 retina specialist providers in Texas.

See all retina specialist providers in Texas

Medicare billing

Part B allowed, 2024
$4,410,739
Medicare patients
1,852
Services billed
49,467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium43$14,855
Bromfenac Sodium45$7,219
Prednisolone Acetate106$5,309
Brimonidine Tartrate250$2,634
Loteprednol Etabonate11$1,812
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$1,134
Timolol Maleate86$928
Dorzolamide Hcl55$891
Ketorolac Tromethamine28$732
Latanoprost50$644
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat14$103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$93$16,66754 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 108 retina specialist providers in Texas.

Other retina specialist in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →